Northwire Canada EditionSaturday, July 11, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
M&A / Property Neutral

EnWave Signs Technology Evaluation and License Option Agreement with Swiss Cannabis Selection AG, Announces Significant Evaluation Results

EnWave's recurring TELOA pipeline masks persistent revenue volatility and cash burn; skepticism already discounted.

By The Northwire Desk — AI Analysis Jun 08, 2026 · 09:00 ENW · 0.235 EnWave Corporation
Executive Summary
  • EnWave Corporation entered into a Technology Evaluation and License Option Agreement (TELOA) with Swiss Cannabis Selection AG (SCS) and Schibano Pharma AG.
  • The agreement allows SCS to evaluate EnWave's proprietary REV™ dehydration technology for medical cannabis and botanical products.
  • Independent testing demonstrated a 2-5 day reduction in drying times without compromising cannabinoid potency, sensory quality, or safety profiles.
  • SCS holds the option to enter a commercial license agreement upon successful completion of the evaluation program.
  • No financial terms, upfront payments, or royalty structures were disclosed.
  • Evaluation activities are expected to commence in the coming months.
Material Impact
  • The TELOA is routine business development consistent with EnWave's historical pattern of signing evaluation agreements. It contains no financial terms, upfront payments, or guaranteed royalties. Given the stock's -27.3% decline since the last earnings print, skepticism about revenue volatility and cash burn was already heavily discounted. The news does not alter the fundamental trajectory or provide near-term cash flow visibility. It is Routine - Neutral.
ENW · Price
Company Overview
  • EnWave Corporation develops and licenses proprietary Radiant Energy Vacuum (REV™) dehydration technology.
  • The business model centers on selling equipment and signing royalty-bearing commercial licenses with food, cannabis, and botanical producers.
  • The company maintains a global footprint with partners across 26 countries, focusing on operational efficiency and product quality preservation.
Read the original news release →

More from EnWave Corporation

May 22, 2026 · 09:00

EnWave’s elephant-hunt partnership with a $20B giant can’t mask the gaping hole in quarterly machine sales and a return to cash‑burn that threatens to swallow the balance sheet.

Earnings May 22, 2026 · 08:30

EnWave Partners with $20B Food Behemoth to Test REV Drying Technology, Betting on a Royalty Windfall

M&A / Property Apr 15, 2026 · 09:00

Egypt Expansion Validates Global Licensing Model

Other Apr 07, 2026 · 09:00

## What the news says

M&A / Property Mar 10, 2026 · 23:29

EnWave signs licence deal with Teagasc

M&A / Property Mar 10, 2026 · 09:00

EnWave Signs License Agreement, and Equipment Purchase Agreement with Teagasc, the Agricultural and Food Development Authority of Ireland

Other